BRISTOL-MYERS SQUIBB COMPANY Extinguishment of Debt, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Extinguishment of Debt, Amount of $6.00 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Notes › Debt
us-gaap:ExtinguishmentOfDebtAmount · last filed 2025-02-12
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for the quarter ending 2022-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for the quarter ending 2022-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for the quarter ending 2022-06-30 was $6.00B.
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for the quarter ending 2022-03-31 was $5.20B, a 48.57% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for fiscal 2022 was $6.00B, a 71.43% increase from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for fiscal 2021 was $3.50B.
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for fiscal 2017 was $337.00M.
- BRISTOL-MYERS SQUIBB COMPANY extinguishment of debt, amount for fiscal 2015 was $1.62B, a 179.04% increase from fiscal 2014.
| Period end | Extinguishment of Debt, Amount 3 month | Extinguishment of Debt, Amount 6 month | Extinguishment of Debt, Amount 9 month | Extinguishment of Debt, Amount 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $6.00B derived: sum of 3 quarters · filed 2025-02-12 | $6.00B 10-K · filed 2025-02-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $6.00B derived: sum of 2 quarters · filed 2023-10-26 | $6.00B 10-Q · filed 2023-10-26 | $11.20B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $6.00B 10-Q · filed 2022-07-27 | $6.00B 10-Q · filed 2023-07-27 | $11.20B derived: sum of 3 quarters · filed 2024-02-13 | $11.20B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $5.20B 10-Q · filed 2023-04-27 | $5.20B derived: sum of 2 quarters · filed 2024-02-13 | $5.20B derived: sum of 3 quarters · filed 2024-02-13 | $5.20B derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $0.00 derived: sum of 2 quarters · filed 2024-02-13 | $0.00 derived: sum of 3 quarters · filed 2024-02-13 | $3.50B 10-K · filed 2024-02-13 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $0.00 derived: sum of 2 quarters · filed 2022-10-26 | $3.50B 10-Q · filed 2022-10-26 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $3.50B 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | $3.50B 10-Q · filed 2022-04-29 | |||
| 2017-12-31 | $337.00M 10-K · filed 2019-02-25 | |||
| 2015-12-31 | $1.62B 10-K · filed 2018-02-13 | |||
| 2014-12-31 | $582.00M 10-K · filed 2017-02-21 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $1.97B derived: sum of 2 quarters · filed 2015-02-13 | $1.97B derived: sum of 3 quarters · filed 2015-02-13 | $2.05B 10-K · filed 2015-02-13 |
| 2012-09-30 | $1.97B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $1.97B derived: sum of 2 quarters · filed 2012-10-24 | $2.05B 10-Q · filed 2012-10-24 | $2.05B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $80.00M 10-Q · filed 2012-07-25 | $80.00M derived: sum of 3 quarters · filed 2014-02-14 | $80.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-03-31 | $80.00M 10-Q · filed 2013-04-25 | $80.00M derived: sum of 2 quarters · filed 2014-02-14 | $80.00M derived: sum of 3 quarters · filed 2014-02-14 | $101.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $0.00 derived: sum of 2 quarters · filed 2014-02-14 | $21.00M derived: sum of 3 quarters · filed 2014-02-14 | $71.00M 10-K · filed 2014-02-14 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $21.00M derived: sum of 2 quarters · filed 2012-10-24 | $71.00M 10-Q · filed 2012-10-24 | |
| 2011-06-30 | $21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $71.00M 10-Q · filed 2012-07-25 | ||
| 2011-03-31 | $50.00M 10-Q · filed 2012-04-26 | |||
| 2010-12-31 | $750.00M 10-K · filed 2013-02-15 | |||
| 2009-12-31 | $117.00M 10-K · filed 2012-02-17 | |||
| 2008-12-31 | $254.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |